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In December 2019, an unexpected outbreak was caused by novel corona virus, 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The lung disease 
caused by SARS-CoV-2 was given the name of the novel coronavirus disease 2019 
(COVID-19) by the World Health Organization (WHO) on February 11, 2020. Since 
its origin in the Hubei province of Wuhan city in China, now it has spread to 218 
countries worldwide. Panic situation created by COVID-19 has compelled research-
ers and doctors to work collaboratively. To combat with the disease, every control 
measures are under consideration from drug discovery to vaccine development. In 
the management of disease, rapid diagnosis is equally important as development of 
vaccine and drug. At present, various diagnostic kits are available for COVID-19.  
With the disease progression, global demand for diagnostics is raising. So, this 
chapter will include the updates on efficient diagnostic assays and future of 
diagnostic.
Keywords: novel corona virus, COVID-19, SARS-CoV-2, diagnosis,  
COVID-19 management
1. Introduction
COVID-19 is now a global health emergency as the number of confirmed 
COVID-19 cases worldwide exceeds 75 million, while the number of global deaths 
exceeds 1 million. WHO has already declared COVID-19 as a public health emer-
gency of international concern (PHEIC) on January 30, 2020 and a pandemic on 
March 11, 2020. New COVID-19 cases and deaths are continuously rising. Globally, 
there have been 106,797,721 confirmed cases and 2,341,145 deaths as per a WHO 
report on February 11, 2021, since the pandemic started [1, 2]. At the start of 
pandemic, the regions of the America and Europe were affected badly, contributed 
85% of new cases and 86% of new deaths globally. The USA and India are top two 
countries with more than 10 million confirmed cases and 313,748 and 145,810 
deaths, respectively [3]. The infection starts to spread from the seafood wholesale 
market in Wuhan, China, while the exact origin of the first case remains unclear. 
Initially, COVID-19 spread, from china to other countries, was due to travelers 
who got infected in China and then moved outside of the China [4]. Countries who 
have reported travel-associated spread were Singapore, Japan, Republic of Korea, 
Malaysia, Vietnam, Australia, the United States of America, Germany, etc. [4, 5]. 
Current, corona virus outbreak is third after the SARS and MERS corona virus out-
breaks. SARS-CoV-2 virus evolved in such a manner that the spread of COVID-19 
is more severe than that of the previous severe acute respiratory syndrome (SARS) 
Biotechnology to Combat COVID-19
2
and the middle east respiratory syndrome (MERS) [6]. Currently, the COVID-19 
pandemic has reached to a threatening new phase. New strains from UK with more 
infectivity are being reported. SARS-CoV-2 belongs to family Coronaviridae and 
order Nidovirales. SARS-CoV-2 stands together with two highly pathogenic viruses, 
SARS-CoV and MERS-CoV as belongs to Betacoronavirus genera [7]. Corona 
viruses are enveloped, positive-sense, single-stranded RNA viruses. Transmission 
of SARS-CoV-2 was initiated first from infected animals to humans and then 
spread rapidly throughout the world via human to human. It spreads via contact to 
respiratory droplets or aerosols through nosocomial transmission from an infected 
to uninfected [8]. As COVID-19 causes enormous human casualties and serious 
economic loss, we are in the urgent need of efficient vaccine and drug develop-
ment against this dreadful virus. Globally, various serious efforts are being made 
in this direction. Governments of many countries have taken immediate action and 
precautionary measures against the virus. Countrywide lockdown were imposed 
to minimize human contact at public places. Social distancing, hygiene, and 
self-quarantine limit social interactions and spread of the disease. To control and 
manage the present pandemic situation the entire world is working and taking nec-
essary steps. To propagate research in this field, governments are providing enough 
funds for scientists and institutions. To combat with the disease, both preventive 
and curative approach is considered. We have many potential vaccine candidates 
that are yet to be approved. Recently in mid November, four groups have reported 
about the efficacy of their vaccines. Vaccination has been started in many countries 
like USA, India. Pfizer-BioNTech COVID-19 vaccine and Moderna’s COVID-19 
vaccine have been approved by FDA recently [9].
To cure the infected patient, several drugs are being tested and used. Drugs that 
are currently in clinical trials are repurposed drugs, which were designed for other 
disease including antiviral and antimalarials [10–13]. Other natural product-based 
formulations are also tested in the management of the disease, for example, Indian 
giloy (Tinospora cordifolia) and ashwagandha [14, 15]. Because of continued spread 
of COVID-19, accurate diagnosis of people becomes necessary. Rapid screening of an 
infected person before transmission onto others is essential to curb the disease. Delay 
and inaccurate diagnosis will give patient a chance to spread the virus. Present pan-
demic has enforced researchers to work at breakneck speed. As a major contribution 
toward diagnostic of COVID-19, various detection methods have been developed. 
Primarily we have molecular-based approaches to confirm suspected cases. Real-
time reverse transcription-polymerase chain reaction (RT-PCR)-based testing is 
the main technique for laboratory diagnosis. Virus antigen- or serological antibody-
based assays are also available with the advantage of a short turnaround time for the 
detection of novel corona virus infection. In this chapter, we will discuss and review 
the available COVID-19 detection methods and future prospectus of the same.
2. Disease biology
SARS-CoV-2 is a novel corona virus. It is spherical and enveloped. SARS-CoV-2 
spans 50–200 nM in diameter. It also contains a typical crown like appearance of 
coronaviruses due to the presence of 20 nM long spikes like structure on its surface 
(Figure 1). Corona viruses are divided into four genera: alpha-coronavirus (α-CoV), 
betacoronavirus (β-CoV), gamma-coronavirus (γ-CoV), and delta-coronavirus 
(δ-CoV). SARS-CoV-2 belongs to β-CoV genera. SARS-CoV-2 is a positive-sense, 
single-stranded RNA virus with large 29 Kb genome size [16, 17]. Genome wide 
study demonstrates that SARS-CoV-2 has sequence similarity with the human and 
bat corona viruses with 82% and 89% sequence homology, respectively [18]. Protein 
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mapping reveals the common protein interaction networks among three CoVs 
(SARS-CoV-1, MERS-CoV, and SARS-CoV-2) in humans, hence identified molecu-
lar mechanisms and potential therapeutic interventions [19]. Genome organization 
includes sequences for leader region, UTRs, replicase, Spike, Envelope, Membrane, 
Nucleocapsid protein, 3′UTR, and poly (A) tail sequence [20]. The spike (S), 
membrane (M), envelope (E), and nucleocapsid (N) are the main four structural 
proteins of SARS-CoV-2 (Figure 2). Spike protein is a club-shaped protein pres-
ent on the surface of virus and also capable of inducing neutralizing antibodies. It 
plays a major role in pathogenesis of SARS-CoV-2. M protein is the conserved and 
abundant protein, which helps virus to maintain its shape. It is also important dur-
ing budding of viral particles from host cells. Role of E protein is important in viral 
pathogenesis. Like M protein, E is also a conserved one. Spike, E, and M together 
form the envelope of SARS-CoV-2. Viral RNA and N protein construct the nucleo-
capsid of virus [21, 22]. SARS-CoV-2 infects the upper respiratory tract in humans 
and cause common cold and flu-like infections. Patients suffer from influenza, sore 
throat, fever, cough, fatigue, and shortness of breath; in few cases, patients also 
experience gastrointestinal issues, such as diarrhea and vomiting. Severity leads to 
multiorgan failure and thus causes death [23, 24]. Old age people and individuals 
suffering from diabetes, hypertension, pulmonary disease, asthma, bronchitis, 
and cardiovascular disorders are at high risk of severe case of corona disease [24]. 
It has been reported that bats are the natural reservoir of SARS-CoV-2 like for 
other human CoVs. SARS-CoV-2 was initially transmitted to humans from infected 
Figure 1. 
Schematic diagram showing SARS-CoV-2 structure.
Figure 2. 
Genome organization of SARS-CoV-2.
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animals in the Wuhan market and then spread globally when human-to-human 
contact occurs via respiratory droplets or aerosols of infected [16].
At molecular level, when the receptor binding domain of spike protein interacts 
with human-ACE2 (angiotensin-converting enzyme 2) receptor, it facilitates 
the binding and subsequent entry of viral particles into host cells. The spike is a 
heavily glycosylated protein and made up of two subunits, the S1 and the S2. The 
S1 subunit is again divided into two domains, that is, an N-terminal (S1 NTP) and 
a C-terminal domain (S1 CTP). RBD is present in C terminal S1 CTP. The RBD 
shows genomic variability. RBD determines the cellular tropism and host range 
to be infected by virus [25–27]. Different strains of Corona viruses have variation 
in binding affinity or human ACE2, thus differ in infection ability, transmission 
rate, and pathogenicity. In comparison to SARS-CoV (~31 nM) and MERS-CoV 
(~16.7 nM), SARS-CoV-2 binding affinity (~4.7 nM) is very high [28].
3. Available diagnostic assays
The severity of the disease varies in diagnosed patients ranging from asymp-
tomatic or mild cases to severe cases. The former can be cured by supportive care 
but the latter depends upon extracorporeal membrane oxygenation. Once patients 
reached to symptomatic stage, they become contagious and start to shed and spread 
the virus. Mass screening and accessible diagnostics always play a vital role to con-
strain the transmission and spread of the virus thus in reduction of mortality rate. 
Proper infection tracing is needed in the assessment of overall health impacts and 
statistics. Till now, there are various strategies for diagnosing COVID-19, which are 
mainly based on viral nucleic acid or antigen detection, and detection of the host’s 
immunological responses. Description about the available test is below:
3.1 Molecular test
Till now, confirmatory diagnosis for COVID-19 is based on molecular 
approaches only. These are considered to be first-line methods. Nucleic acid testing 
based on real-time reverse transcription-polymerase chain reaction (RT-PCR) is 
the main technique for laboratory diagnosis. It involves nucleic acid amplifica-
tion test to detect unique sequences within SARS-CoV-2 genome. RT-PCR is a 
two step process. In the first step, viral RNA is converted to cDNA using a reverse 
transcriptase enzyme, and the second step involves the amplification of only the 
selected region using gene-specific primers and further quantification is carried 
out as fluorescently labeled hydrolysis probe produces fluorescent signals [29]. 
Since the release of entire genome sequence of the virus from scientists of China, 
many countries, such as England, Germany, South Korea, Turkey, Russia, the 
USA, India, and China, launched their clinical-grade RT-PCR kits for SARS-CoV-2 
detection. For RT-PCR kits, samples are taken from various infected parts of the 
body, including nasopharyngeal, oropharyngeal, or nasal swabs, upper and lower 
respiratory tract aspirates, bronchoalveolar lavage, and the sputum [30]. Main 
components in RT-PCR-based Kits are the reverse transcription and amplifica-
tion enzymes, specific primers and probes for amplification of the selected viral 
genome regions, and authorized reagents for negative, positive, and internal 
controls, target genes, corresponding primer, and probe sequences used in 
RT-PCR kits so far for SARS-CoV-2 detection. Various research groups have been 
proposed the use of different set of target genes, corresponding primer, and probe 
sequences. Generally, the commercial kits based on the RT-PCR are only operated 
in well-equipped laboratory conditions and require skilled persons [31]. Pixel by 
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LabCorp COVID-19 Test Home Collection Kit made home collection possible. It 
contains a specimen biohazard bag, pre-labeled return FedEx envelope, saline 
tube, insulated specimen pouch, nasal specimen collection, swab gel pack (for 
sample cooling), shipping box, and the user guideline [32].
Other molecular-based technologies like LAMP, RT-LAMP, and rRT-LAMP 
amplify nucleic acid isothermally without any use of a thermocycler. DNA poly-
merase along with multiple primers, six or four as inner and outer primers, is 
used to amplify the target sequence. In RT-LAMP, analysis of results is done by 
the change of color, fluorescence, or turbidity in the PCR tubes, which makes it a 
simple and practical technique. Use of multiple primers gives specificity in results. 
RT-LAMP is a fast and specific method which completes detection of SARS-CoV-2 
in 1–2 h without any need of a trained molecular biologist [33].
Another isothermal nucleic acid amplification based assay is SHERLOCK assay, 
which also employs the clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated system (Cas) enzymology for the detection of the 
target nucleic acid. Upon the binding of CRISPR RNA to the target sequence, the 
nonspecific endonuclease activity of Cas13 or Cas12 starts, leading to the cleavage 
of nearby reporter RNAs which generates signal for detection. SHERLOCK is a 
very specific and sensitive assay for diagnosis as Cas13 does not get activated if two 
or more mismatches are present in the target RNA, and it can easily discriminate 
between SARS-CoV-2 and other similar viruses [34].
Advantages:
• RT-PCR is the gold standard for SARS-CoV-2 because it can directly measure 
the viral genomic parts.
• It is most reliable method for SARS-CoV-2 detection.
Disadvantages:
• It is a tedious, time-consuming protocol.
• When infection of the virus starts to move toward the lower respiratory track, 
sample collected from throat may give us false negative results.
• It requires laboratories with biosafety level II facility so not suitable for rapid 
testing.
• Limited number of assay can be performed.
• Sensitivity is low at early stage of infection.
• It can detect the active infection in a patient, not the recovered.
3.2 Antibody test
In an antibody test, existence and concentration of IgG and IgM antibodies is 
measured in the blood/serum/plasma samples of infected patients. It can determine 
if the body encounters with a pathogen like SARS-CoV-2 virus. Common antibody 
tests are based on lateral flow type assays (LFA) and enzyme-linked immunosor-
bent type assays (ELISA) [35]. An antibody LFA test detects the presence of the spe-
cific antibodies in the patient’s blood sample. A SARS-CoV-2 antigen(s) is already 
immobilized on a sample pad. The sample is loaded onto the sample pad at end port 
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where Colloidal gold (CG) or quantum dot (QD)-labeled detection antibodies are 
present. Sample along with labeled antibodies moves through the strip by capillary 
action to the test line and control line [36]. If SARS-CoV-2 antibodies are present in 
the sample, they will be captured by the labeled detection antibody and will bind to 
the immobilized antigen at test line. Even if the SARS-CoV-2 antibodies are absent 
in the sample, the gold-labeled antibodies will still be captured at the control line 
and a band on the strip will appear due to the accumulation of CG or QD.
ELISA tests are performed in multi-well plates coated with the recombinant viral 
antigen. If antibodies (IgG or IgM) against the SARS-CoV-2 antigen are present in 
the sample, a binding between coated antigen and SARS-CoV-2 antibodies occurs. 
Then, secondary anti-human antibodies are added to bind with SARS-CoV-2 Ag-Ab 
complex. Secondary antibodies are enzyme labeled (usually horseradish peroxi-
dase). Upon addition of an enzyme substrate, a color-changing reaction happens. In 
the absence of the antibody of interest, no color is generated. In a modified version 
of ELISA, that is, chemiluminescent immunoassays (CLIA), the binding of the 
secondary antibody is confirmed by a chemiluminescent substrate [37]. ELISA test 
is a multistep process that demands a well-equipped lab, but LFA can be used at 
home without any training [38, 39].
3.3 Antigen test
An antigen is a non-self particle/fragment/molecule that can induce the 
immune system to produce antibody against pathogens, hence protects the body. 
The antigen test is also an immunoassay which detects viral components (i.e., 
S glycoprotein, M protein, or released N protein) or directly virus. Unlike the 
antibody-based methods, antigen tests detect the active viral infection, not the 
recovery situation. Because antigens precede antibodies, antigen test could be more 
reliable than antibody tests. Antigen tests can also be operated on LFA strips for 
rapid detection or in ELISA plates for increased sensitivity, and high throughput 
uses [29, 40].
Advantages:
• Antigen tests completes in 15–20 minutes.
• Antigen tests do not require well-equipped labs and highly trained personnel.
• It is cost-effective for both mass screening and application.
• Specificity is higher as it detects direct viral antigen.
Disadvantages:
• Low sensitivity as it requires high level of viral load for testing.
3.4 Other methods
Several other methods for diagnosis have been proposed. Some of them are 
novel and at research stage and some are based on conventional technology, 
for example, computed tomography (CT) scans. Aptamers functionalized with 
quantum dots (Qds), paper-based assays, semiconductor-based binding assays, 
surface plasmon resonance-based assays, piezoelectric immune sensors, and 
electrochemical sensors have been developed. A CT scan reveals about the pos-
sible abnormalities due to the viral infection in the chest [41]. Other detection 
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technologies developed for the identification of SARS-CoV-2 are based on the pres-
ence of different biomarkers in bio-fluids. Increased concentrations of C-reactive 
protein, D-dimer, lymphocytes, leukocytes, and blood platelets and elevated levels 
of serum urea, creatinine, and cystatin C can be utilized for diagnosis. Biosensors 
based on plasmonic sensing and field effect transistor (FET) have been developed 
for mass screening. Localized surface plasmon resonance (LSPR) sensor detects the 
SARS-CoV-2 nucleic acid with combined use of photo-thermal effect and plasmon 
sensing [42]. In FET-based biosensors, biological molecules modify the charge 
distribution of the surface, or they generate a surface potential by binding to the 
surface, which is further measured as a conductance value [43]. For mass screen-
ing of such pandemic, we need a global e-platform to control the spread of the 
virus which is now possible with emergence of data science and advancement in 
mobile telecommunications. In this view, mHealth is a useful development, which 
is an application of mobile devices like smarphones, onboard optics/sensor based 
patient monitoring devices, and wireless/Bluetooth technology. Such advance-
ments lead to easy collection of large epidemiological data based on contact trac-
ing, automation of inventory mangement, digital, and fast reporting of the new 
cases. It can also help further in supply chain management of limited resources 
for affected areas and also help government in policy making [44]. Indian govern-
ment has also launched “Aarogya setu” app during COVID-19 pandemic [45]. 
Information about some of the COVID-19 diagnostic kits based on above discussed 
methods are listed in Table 1.
4. Future of diagnostic and conclusion
COVID-19 has emerged as the most severe and terrifying viral infection encoun-
tered by us. Considering present pandemic situation, researchers from all around 
the globe have put strenuous efforts to develop test for COVID-19 diagnosis. They 
aim to develop a test that shows fast and accurate results, without compromising 
on the sensitivity and selectivity of the assay. Although present vaccine regime 
against COVID-19 has lessen the burden on health sector still, we are not aware of 
the long-term effects of COVID-19. Early medical interventions are only possible if 
diagnosis of the diseases is done at earlier stages. Many diagnostic tests have been 
developed which differ from sensitivity to specificity. Every test has disadvantages 
and advantages over the other methods (Figure 3).
Method Developer company References
RT-PCR Viractor Erofins [46]
RT-PCR Bosch [47]
RT-LAMP Abbott Laboratories [48]
SHERLOCK Howard Hughes Medical Institute [34]
CMIA Abbott Laboratories [49]
Lateral flow assay Pharmact AG [50]
Lateral flow assay ChemBioDiagnostic Systems [51]
ELISA Bio-Rad [52]
Antigen test N protein LFA Quidel Corporation [53]
Table 1. 
Developed kits for COVID-19 diagnosis.
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The genome-based detection of SARS-CoV-2 is solely relied on the RT-PCR 
method. Existing RT-PCR-based assays are not sensitive enough to detect the 
COVID-19 in the early stages of infection. Serology tests are rapid and apt for vast 
screening but they cannot confirm the presence of the active infection. Antigen-
based test are also very promising but need development. Despite the excellent 
effort put by researchers globally, we are still in the need of developing an assay 
which can detect the SARS-CoV-2 in individuals at the initial stage. For this pur-
pose, early stage biomarkers of COVID-19 should be identified and utilized for 
development of new assays. In severe conditions, CT scan can be used as comple-
mentary diagnostic tool along with RT-PCR [54]. It is reported that physicians took 
help of CT SCAN to effectively detect COVID-19 infection in RT-PCR false-negative 
cases. Antigen tests can also be performed along with RT-PCR to support present 
diagnostics and accelerate the detection speed worldwide. Different manufacturers 
and laboratories are using various parameters and conditions for testing. We do 
not have any universal standard for testing. Specimen and collection time needs 
to be optimized. Such standardization will give consistency in test results [55]. 
More effort toward research is required for further understanding of the influence 
of diagnostics. There is still scope in exploring about SARS-CoV-2 virus biology 
and COVID-19 pathology. Understanding of virus will help in developing more 
accurate diagnostic and effective treatment. Further research is required in the 
field of COVID-19 diagnostics to develop a rapid and automated diagnostic test 
with more sensitivity and specificity. In light of this, the government of India has 
also announced the call for various research projects for funding. In this direction 
public, clinicians, industries, and government all should work in coordination to 
fight against SARS-CoV-2. Global coordination between them is in high demand.
Figure 3. 
Comparison of different COVID-19 diagnostic assay.
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